MiR-128-3p promotes the progression of deep venous thrombosis through binding SIRT1.

IF 1.6 4区医学 Q3 PERIPHERAL VASCULAR DISEASE

Phlebology Pub Date : 2023-09-01 Epub Date: 2023-07-19 DOI:10.1177/02683555231190268

Jinan Han, Wanjiang Hao, Yanping Ma, Yanqiu Hou

{"title":"MiR-128-3p promotes the progression of deep venous thrombosis through binding SIRT1.","authors":"Jinan Han, Wanjiang Hao, Yanping Ma, Yanqiu Hou","doi":"10.1177/02683555231190268","DOIUrl":null,"url":null,"abstract":"Objectives: This research aimed to study the effect of microRNA-128-3p (miR-128-3p) on deep venous thrombosis (DVT).Method: The 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay, Transwell chamber method, and flow cytometry technique were used in the cell experiments. Potential interconnection between miR-128-3p and silent information regulator sirtuin 1 (SIRT1) was revealed by luciferase activity. The concentration of miR-128-3p and mRNA SIRT1 was assessed by quantitative reverse transcription polymerase chain reaction (qRT-PCR). The receiver operating characteristic (ROC) curve was used to test the predictive effect of miR-128-3p in DVT.Results: Decreased miR-128-3p expression was beneficial to cell proliferation and migration and inhibited inflammation, apoptosis, and adhesion of human umbilical vein endothelial cells (HUVECs). The impacts of miR-128-3p on HUVECs were achieved by targeting SIRT1. MiR-128-3p was upregulated in patients with DVT, and it was of great significance in differentiating patients with DVT.Conclusion: Overexpression of miR-128-3p might become a biomarker for patients with DVT.","PeriodicalId":20139,"journal":{"name":"Phlebology","volume":" ","pages":"540-549"},"PeriodicalIF":1.6000,"publicationDate":"2023-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"1","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Phlebology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1177/02683555231190268","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2023/7/19 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"PERIPHERAL VASCULAR DISEASE","Score":null,"Total":0}

引用次数: 1

Abstract

Objectives: This research aimed to study the effect of microRNA-128-3p (miR-128-3p) on deep venous thrombosis (DVT).

Method: The 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay, Transwell chamber method, and flow cytometry technique were used in the cell experiments. Potential interconnection between miR-128-3p and silent information regulator sirtuin 1 (SIRT1) was revealed by luciferase activity. The concentration of miR-128-3p and mRNA SIRT1 was assessed by quantitative reverse transcription polymerase chain reaction (qRT-PCR). The receiver operating characteristic (ROC) curve was used to test the predictive effect of miR-128-3p in DVT.

Results: Decreased miR-128-3p expression was beneficial to cell proliferation and migration and inhibited inflammation, apoptosis, and adhesion of human umbilical vein endothelial cells (HUVECs). The impacts of miR-128-3p on HUVECs were achieved by targeting SIRT1. MiR-128-3p was upregulated in patients with DVT, and it was of great significance in differentiating patients with DVT.

Conclusion: Overexpression of miR-128-3p might become a biomarker for patients with DVT.

查看原文本刊更多论文

MiR-128-3p通过结合SIRT1促进深静脉血栓形成的进展。

目的：研究微小RNA-128-3p（miR-128-3p）对深静脉血栓形成（DVT）的影响。荧光素酶活性揭示了miR-128-3p和沉默信息调节因子SIRT1之间的潜在相互作用。通过定量逆转录聚合酶链反应（qRT-PCR）评估miR-128-3p和mRNA SIRT1的浓度。结果：miR-128-3p表达减少有利于细胞增殖和迁移，抑制人脐静脉内皮细胞（HUVECs）的炎症、凋亡和粘附。miR-128-3p对HUVECs的影响是通过靶向SIRT1来实现的。MiR-128-3p在DVT患者中表达上调，对鉴别DVT患者具有重要意义。结论：MiR-128-3p的过表达可能成为DVT患者的生物标志物。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Phlebology 医学-外周血管病

CiteScore

3.30

自引率

11.80%

发文量

审稿时长

6-12 weeks

期刊介绍： The leading scientific journal devoted entirely to venous disease, Phlebology is the official journal of several international societies devoted to the subject. It publishes the results of high quality studies and reviews on any factor that may influence the outcome of patients with venous disease. This journal provides authoritative information about all aspects of diseases of the veins including up to the minute reviews, original articles, and short reports on the latest treatment procedures and patient outcomes to help medical practitioners, allied health professionals and scientists stay up-to-date on developments. Print ISSN: 0268-3555